Xarelto misses in 1Q but Bayer raises FY expectations
This article was originally published in Scrip
Executive Summary
Bayer saw net profits fall in the first quarter of 2015 due to higher R&D expenses and integration costs. Meanwhile, oral anticoagulant Xarelto (rivaroxaban) also failed to meet expectations.